Dr. Bridget A. Azera, MD

Dr. Azera practices at Yale New Haven Health Westerly Hospital in Westerly, Rhode Island, part of Yale New Haven Health System.

Dr. Azera's NPI, 1861997272, was assigned on March 27, 2018. Dr. Azera holds New York license 315603.

Dr. Azera's primary practice is Yale New Haven Health Westerly Hospital, at 25 Wells Street, Westerly, RI 02891 in Washington County. The practice phone is (401) 596-6000.

Dr. Azera's primary practice is Yale New Haven Health Westerly Hospital in Westerly, Rhode Island, part of Yale New Haven Health System. Dr. Azera is also affiliated with JFK University Medical Center. The medical group on file is Ipc Hospitalists Of New England. Dmand AI also links Dr. Azera to 3 more hospitals, 9 medical groups and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Azera practices, 6 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Azera's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dmand AI has Dr. Azera's licenses on file in 2 states: New York and New Hampshire.

CMS data shows 1,240 Medicare services from Dr. Azera across 8 procedure codes in 2024, for 464 Medicare patients. Medicare paid $110,354 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 464 Medicare patients who saw Dr. Azera in 2024. The largest group is 75 to 84, with 182 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 17% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Azera's median patient age at 69, with 51% women.

In 2024, Dr. Azera wrote 452 Medicare Part D claims for 179 patients. 88% of them were for generic drugs. CMS names the drug for 192 of them, across 10 drugs with 11 or more claims each, at $13,625 in total drug cost. In 2023, CMS named 44 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Azera for performance year 2024, reported as part of a group. Dr. Azera accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 2 general payments to Dr. Azera from 2 drug and device companies in 2023. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $28.